“This cost-utility analysis confirms what many of us in clinical practice have observed,” said Nathan Lighthizer, OD, FAAO, lead investigator of the study and Professor and Dean for the NSU Oklahoma ...
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial The economic evaluation, conducted from societal ...
US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia For the model, we used ...
Assuming two procedures over a 1-year time horizon, TearCare demonstrated a cost-saving advantage over CsA, reducing per-patient costs by $903 annually. Patients receiving TearCare experienced an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results